Stocks Health care SBFM
NASDAQ · Health careSunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc. brought in $35.3M of revenue over the twelve months to June 30, 2026, down 2.7% from a year earlier. It posted a net loss of $5.8M. In fiscal 2025 capital spending exceeded operating cash flow by $5.5M. At June 30, 2026 it held $13.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Sunshine Biopharma Inc.
- Net worth
- Sunshine Biopharma Inc. has a market value (market cap) of $10.7M at the latest share price, and shareholders' equity of $27.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $36.3M (+4.1% year on year), with a net loss of $6M. Over the 12 months to June 30, 2026: revenue $35.3M, net loss $5.8M.
- Cash flow
- In fiscal 2025 operations used $5.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Sunshine Biopharma Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Sunshine Biopharma Inc. does
Sunshine Biopharma Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SBFM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $36.3M | -$6M | -$1.44 | -$5.5M |
| 2024 | $34.9M | -$5.1M | -$7.32 | -$14.2M |
| 2023 | $24.1M | -$4.5M | -$351.36 | -$8.9M |
| 2022 | $4.3M | -$26.7M | -$3,254.70 | -$5.4M |
| 2021 | $228.4K | -$12.4M | -$8,802.49 | -$1.8M |
| 2020 | $71.4K | -$2.8M | -$5,048.49 | -$658.5K |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SBFM ranks in Health care
Latest SEC filings
What Sunshine Biopharma Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Passive stake changed SCHEDULE 13G/A
- October 2, 2026IPO registration S-1
- September 28, 2026Form DEF 14C filing DEF 14C
- September 16, 2026Form PRE 14C filing PRE 14C
- September 16, 2026
- September 11, 2026Other event 8-K
- August 28, 2026IPO registration S-1
- August 28, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 1.6% to $9.3M versus the same quarter last year; diluted EPS -$1.15 versus -$0.82.
Insider trades
What the people running Sunshine Biopharma Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 7, 2026 | Natan DavidDirector | Received as pay | 58,300 | - |
| April 14, 2026 | Natan DavidDirector | Received as pay | 100,000 | - |
Who owns SBFM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Mitchell P. Kopin13G, passive with 2 related filers | 9.99% | August 13, 2026 |
| Bigger Michael13G, passive with 6 related filers | 9.47% | May 21, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 68,300 shares in total, about $187.8K at the last price.
| Holder | Shares |
|---|---|
| Natan DavidDirector | 68,300 |
Questions about SBFM
What does Sunshine Biopharma Inc. do?
Sunshine Biopharma Inc. is a company in the Health care sector, listed on NASDAQ as SBFM. Its shares trade on NASDAQ under the ticker SBFM.
What is Sunshine Biopharma Inc.'s net worth?
Sunshine Biopharma Inc. has a market value (market cap) of $10.7M at the latest share price, and shareholders' equity of $27.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Sunshine Biopharma Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $5.8M on revenue of $35.3M.
How much revenue does Sunshine Biopharma Inc. make?
Over the twelve months to June 30, 2026 Sunshine Biopharma Inc. reported revenue of $35.3M. That is 2.7% less than a year earlier.
When did Sunshine Biopharma Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from October 5, 2026.
When is Sunshine Biopharma Inc.'s next earnings report?
Sunshine Biopharma Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SBFM with
Follow SBFM
Get an email when Sunshine Biopharma Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Sunshine Biopharma Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.